Skip Navigation



NDT Advance Access published online on May 25, 2006
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfl194
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/8/2096    most recent
gfl194v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lee, S.
Right arrow Articles by Park, S. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, S.
Right arrow Articles by Park, S. K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Received December 8, 2005
Accepted March 21, 2006

Original Article

Rosiglitazone ameliorates cisplatin-induced renal injury in mice

Sik Lee 1, Won Kim 1, Sang-Ok Moon 1, Mi Jeong Sung 1, Duk Hoon Kim 1, Kyung Pyo Kang 1, Yong Bum Jang 1, Jung Eun Lee 1, Kyu Yun Jang 2, and Sung Kwang Park 1 *

1 Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, Republic of Korea
2 Department of Pathology, Renal Regeneration Laboratory, Research Institute of Clinical Medicine, Chonbuk National University Medical School, Jeonju, Republic of Korea

* To whom correspondence should be addressed.
Sung Kwang Park, E-mail: parksk{at}chonbuk.ac.kr



  Abstract

Background. Inflammatory mechanisms may play an important role in the pathogenesis of cisplatin nephrotoxicity. Agonists of the peroxisome proliferator-activated receptor-{gamma} (PPAR{gamma}), such as rosiglitazone, have been recently demonstrated to regulate inflammation by modulating the production of inflammatory mediators and adhesion molecules. The purpose of this study was to examine the protective effects of rosiglitazone on cisplatin nephrotoxicity and to explore the mechanism of its renoprotection.

Methods. Mice were treated with cisplatin with or without pre-treatment with rosiglitazone. Renal functions, histological findings, aquaporin 2 (AQP2) and adhesion molecule expression, macrophage infiltration and tumour necrosis factor-{alpha} (TNF-{alpha}) levels were investigated. The effect of rosiglitazone on nuclear factor (NF)-{kappa}B activity and on viability was examined using cultured human kidney (HK-2) cells.

Results. Rosiglitazone significantly decreased both the damage to renal function and histological pathology after cisplatin injection. Pre-treatment with rosiglitazone reduced the systemic levels of TNF-{alpha} and down-regulated adhesion molecule expression in addition to the infiltration of inflammatory cells after cisplatin administration. Rosiglitazone restored the decreased AQP2 expression after cisplatin treatment. Pre-treatment with rosiglitazone blocked the phosphorylation of the p65 subunit of NF-{kappa}B in cultured HK-2 cells. Rosiglitazone had a protective effect via a PPAR{gamma}-dependent pathway in cisplatin-treated HK-2 cells.

Conclusion. These results showed that pre-treatment with rosiglitazone attenuates cisplatin-induced renal damage through the suppression of TNF-{alpha} overproduction and NF-{kappa}B activation.

Keywords: cisplatin; nuclear factor-{kappa}B; rosiglitazone; tumour necrosis factor-{alpha}.
The authors wish to be known that, in their opinion, the first two authors contributed equally to this work.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
K. P. Kang, D. H. Kim, Y. J. Jung, A. S. Lee, S. Lee, S. Y. Lee, K. Y. Jang, M. J. Sung, S. K. Park, and W. Kim
Alpha-lipoic acid attenuates cisplatin-induced acute kidney injury in mice by suppressing renal inflammation
Nephrol. Dial. Transplant., October 1, 2009; 24(10): 3012 - 3020.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Jiang and Z. Dong
Regulation and Pathological Role of p53 in Cisplatin Nephrotoxicity
J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 300 - 307.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. D. Girnun, L. Chen, J. Silvaggi, R. Drapkin, L. R. Chirieac, R. F. Padera, R. Upadhyay, S. B. Vafai, R. Weissleder, U. Mahmood, et al.
Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin
Clin. Cancer Res., October 15, 2008; 14(20): 6478 - 6486.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
J. Luo, T. Tsuji, H. Yasuda, Y. Sun, Y. Fujigaki, and A. Hishida
The molecular mechanisms of the attenuation of cisplatin-induced acute renal failure by N-acetylcysteine in rats
Nephrol. Dial. Transplant., July 1, 2008; 23(7): 2198 - 2205.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
L. H. Lu, D.-J. Oh, B. Dursun, Z. He, T. S. Hoke, S. Faubel, and C. L. Edelstein
Increased Macrophage Infiltration and Fractalkine Expression in Cisplatin-Induced Acute Renal Failure in Mice
J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 111 - 117.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.